在一名范可尼贫血患者中进行吉非替尼试验，该患者患有多个鳞状细胞癌和肝细胞癌。
Gefitinib trial in a fanconi's anemia patient with multiple squamous cell carcinomas and hepatocellular carcinoma.
机构信息
Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea.
出版信息
Cancer Res Treat. 2005 Dec;37(6):370-3. doi: 10.4143/crt.2005.37.6.370. Epub 2005 Dec 31.
Abstract
FA (Fanconi's Anemia) is an autosomal recessive disorder that is characterized by pancytopenia with bone marrow hypoplasia, diverse congenital abnormalities and an increased predisposition towards malignancy. The mainstay of the treatment for these cancers has been surgery, because of the hypersensitive reactions of FA patients to DNA cross- linking agents or radiation. Therefore, there has been no effective therapy for advanced squamous cell carcinoma. We report here on a patient suffering from advanced multiple squamous cell carcinoma and hepatocellular carcinoma along with an FA, and this patient was treated with gefitinib.
摘要
范可尼贫血（FA）是一种常染色体隐性遗传疾病，其特征是全血细胞减少伴骨髓发育不良、多种先天性异常和恶性肿瘤易感性增加。由于 FA 患者对 DNA 交联剂或辐射的超敏反应，这些癌症的主要治疗方法一直是手术。因此，对于晚期鳞状细胞癌没有有效的治疗方法。我们在此报告一例患有晚期多发性鳞状细胞癌和肝细胞癌以及 FA 的患者，并使用吉非替尼对其进行治疗。
相似文献
1
Gefitinib trial in a fanconi's anemia patient with multiple squamous cell carcinomas and hepatocellular carcinoma.在一名范可尼贫血患者中进行吉非替尼试验，该患者患有多个鳞状细胞癌和肝细胞癌。
Cancer Res Treat. 2005 Dec;37(6):370-3. doi: 10.4143/crt.2005.37.6.370. Epub 2005 Dec 31.
2
The association of Fanconi's anemia and squamous cell carcinoma.范可尼贫血与鳞状细胞癌的关联。
Cancer. 1983 Sep 1;52(5):926-8. doi: 10.1002/1097-0142(19830901)52:5<926::aid-cncr2820520530>3.0.co;2-t.
3
Squamous cell vulvar carcinoma associated with Fanconi's anemia: a case report.与范科尼贫血相关的外阴鳞状细胞癌：一例报告。
Int J Gynecol Cancer. 2002 Mar-Apr;12(2):220-2. doi: 10.1046/j.1525-1438.2002.01090.x.
4
Carcinoma of the esophagus associated with Fanconi's anemia.与范科尼贫血相关的食管癌。
J Clin Gastroenterol. 1981 Jun;3(2):171-4. doi: 10.1097/00004836-198106000-00012.
5
[Fanconi's anemia with squamous cell carcinoma--a case report and a review of literature].范可尼贫血合并鳞状细胞癌——一例报告及文献复习
Rinsho Ketsueki. 1989 Nov;30(11):1992-6.
6
Squamous cell carcinoma of base of tongue in a patient with Fanconi's anemia treated with radiation therapy: case report and review of literature.舌根鳞状细胞癌合并范可尼贫血患者接受放射治疗：病例报告及文献复习。
Head Neck. 2010 Oct;32(10):1422-7. doi: 10.1002/hed.21211.
7
Head and neck carcinoma in Fanconi's anaemia--report of a case and review of the literature.范可尼贫血患者的头颈部癌——1例报告及文献复习
Eur J Cancer B Oral Oncol. 1995 Jan;31B(1):68-72. doi: 10.1016/0964-1955(94)00044-5.
8
[Cytogenetic Diagnosis of Fanconi's Anemia-Distinguishing Fanconi's Anemia from Aplastic Anemia].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2000 Sep;8(3):216-221.
9
Squamous cell carcinoma of the tongue in a patient with Fanconi's anemia: a case report and review of the literature.范可尼贫血患者的舌鳞状细胞癌：一例报告并文献复习
Ann Hematol. 2002 May;81(5):294-8. doi: 10.1007/s00277-002-0455-6. Epub 2002 May 3.
10
Squamous cell carcinoma of the hypopharynx in a young woman with Fanconi's anemia.一名患有范可尼贫血的年轻女性的下咽鳞状细胞癌。
Braz J Otorhinolaryngol. 2006 Nov-Dec;72(6):845-8. doi: 10.1016/s1808-8694(15)31054-5.
引用本文的文献
1
Opening of a phase Ib/II study to investigate the safety and efficacy of Afatinib in patients with Fanconi anemia and unresectable locally advanced or metastatic head and neck squamous cell carcinoma.一项Ib/II期研究启动，旨在调查阿法替尼在范可尼贫血患者以及不可切除的局部晚期或转移性头颈部鳞状细胞癌患者中的安全性和疗效。
BMC Cancer. 2025 Aug 26;25(1):1374. doi: 10.1186/s12885-025-14619-6.
2
Treatment of Fanconi Anemia-Associated Head and Neck Cancer: Opportunities to Improve Outcomes.范可尼贫血相关头颈部癌症的治疗：改善预后的机会。
Clin Cancer Res. 2021 Oct 1;27(19):5168-5187. doi: 10.1158/1078-0432.CCR-21-1259.
3
Oral Tongue Cancer in a Patient with Fanconi Anemia: A Case Report and Literature Review.范可尼贫血患者的口腔舌癌：一例报告及文献综述
Cancer Manag Res. 2021 Apr 12;13:3145-3154. doi: 10.2147/CMAR.S301582. eCollection 2021.
本文引用的文献
1
Investigation of HER2 overexpression in non-small cell lung cancer.非小细胞肺癌中HER2过表达的研究
Anticancer Res. 2005 Jul-Aug;25(4):3061-6.
2
Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.人表皮生长因子受体2（HER2）基因拷贝数增加与表皮生长因子受体阳性的非小细胞肺癌患者对吉非替尼治疗的反应相关。
J Clin Oncol. 2005 Aug 1;23(22):5007-18. doi: 10.1200/JCO.2005.09.111.
3
Targeting EGFR in non-small-cell lung cancer.非小细胞肺癌中表皮生长因子受体的靶向治疗
N Engl J Med. 2005 Jul 14;353(2):200-2. doi: 10.1056/NEJMe058113.
4
Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.西南肿瘤协作组研究：荧光原位杂交检测发现，细支气管肺泡癌亚型患者中表皮生长因子受体基因拷贝数增加与对吉非替尼的敏感性增加相关。
J Clin Oncol. 2005 Oct 1;23(28):6838-45. doi: 10.1200/JCO.2005.01.2823. Epub 2005 Jul 5.
5
Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells.表皮生长因子受体（EGFR）相关蛋白在结肠癌细胞和乳腺癌细胞中抑制EGFR家族的多个成员。
Mol Cancer Ther. 2005 Mar;4(3):435-42. doi: 10.1158/1535-7163.MCT-04-0280.
6
Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.吉非替尼（易瑞沙，ZD1839）：一种治疗实体瘤的新型靶向方法。
Bull Cancer. 2004 May 1;91(5):E70-6.
7
Molecular markers to predict response to gefitinib: EGFR, ErbB-2, or more?
J Clin Oncol. 2004 May 15;22(10):2035-6; author reply 2036-7. doi: 10.1200/JCO.2004.99.337.
8
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.ZD1839用于复发性或转移性头颈部鳞状细胞癌的II期试验。
J Clin Oncol. 2003 May 15;21(10):1980-7. doi: 10.1200/JCO.2003.10.051.
9
ZD1839 (Iressa): for more than just non-small cell lung cancer.ZD1839（易瑞沙）：作用不止于非小细胞肺癌。
Oncologist. 2002;7 Suppl 4:16-24. doi: 10.1634/theoncologist.7-suppl_4-16.
10
ZD1839: targeting the epidermal growth factor receptor in cancer therapy.ZD1839：癌症治疗中对表皮生长因子受体的靶向作用
Expert Opin Investig Drugs. 2002 Jun;11(6):837-49. doi: 10.1517/13543784.11.6.837.
Zotero 插件